The board of directors of Sino Biopharmaceutical Limited announced that, "Mirabegron Sustained-release Tablets", a drug developed by the Group for urinary system, has been granted the drug registration certificate by the National Medical Products Administration of China. The product was filed as a drug under Chemicals Category 4, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs, being the second generic drug of its kind that has obtained approval for drug registration in China. Mirabegron is a selective beta-adrenergic receptor agonist for the auxiliary treatment of urgent urination, frequent urination and/or urge incontinence in adults with overactive bladder (OAB).

By acting on the beta-adrenergic receptors, Mirabegron selectively relaxes the detrusor muscle of bladder and facilitates urine storage, thereby increasing bladder capacity and lengthening the voiding interval without affecting bladder emptying. Mirabegron has been included in the "List of Second Batch of Encouraged Generic Drugs" issued by the Center for Drug Evaluation (CDE) of the National Medical Products Administration and was admitted to the national medical insurance in 2020 in China. The approval of Mirabegron Sustained-release Tablets of the Group provides a new medication option for patients with overactive bladder in China.